中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2009年
3期
196-198
,共3页
孟弃逸%刘喆%郭丽丽%徐丽艳%朱允中%史鹤玲%唐俊舫
孟棄逸%劉喆%郭麗麗%徐麗豔%硃允中%史鶴玲%唐俊舫
맹기일%류철%곽려려%서려염%주윤중%사학령%당준방
癌,非小细胞肺%抗肿瘤联合化疗方案%长春花生物碱类%顺铂
癌,非小細胞肺%抗腫瘤聯閤化療方案%長春花生物堿類%順鉑
암,비소세포폐%항종류연합화료방안%장춘화생물감류%순박
Carcinoma,non-small-cell lung%Antineoplastic combined chemotherapy protocols%Vinca alkaloids%Cisplatin
目的 研究长春瑞滨与铂类联合治疗70岁以上非小细胞肺癌患者的疗效和毒副反应.方法 老年肺癌患者共入选100例.化疗组50例,采用长春瑞滨25 mg/m2第1天和第5天,顺铂60～70mg/m2或卡铂250 mg/m2第2天,每4周为1个周期,连用2～4周期.对照组50例,为同期70岁以上患者,资料完整且未做治疗.结果 治疗组45例可评价疗效,部分缓解16例,有效率35.6%,1年生存率37.8%,中位生存期9.8个月;对照组中位生存期4.0个月.治疗组50例均可评价毒副反应,世界卫生组织(WHO)毒副反应标准Ⅲ度白细胞、中性白细胞、贫血发生率分别为38.0%、52.0%和2.2%,IV度中性粒细胞减少发生率35.5%.WHO毒副反应标准Ⅲ度非血液学毒性乏力、呕吐和便秘发生率分别为22.0%、14.0%和8.0%,因毒性反应终止治疗共5例.结论 长春瑞滨与铂类联合治疗高龄非小细胞肺癌有效且毒副反应可耐受.疗效稳定的患者也可从化疗受益.
目的 研究長春瑞濱與鉑類聯閤治療70歲以上非小細胞肺癌患者的療效和毒副反應.方法 老年肺癌患者共入選100例.化療組50例,採用長春瑞濱25 mg/m2第1天和第5天,順鉑60～70mg/m2或卡鉑250 mg/m2第2天,每4週為1箇週期,連用2～4週期.對照組50例,為同期70歲以上患者,資料完整且未做治療.結果 治療組45例可評價療效,部分緩解16例,有效率35.6%,1年生存率37.8%,中位生存期9.8箇月;對照組中位生存期4.0箇月.治療組50例均可評價毒副反應,世界衛生組織(WHO)毒副反應標準Ⅲ度白細胞、中性白細胞、貧血髮生率分彆為38.0%、52.0%和2.2%,IV度中性粒細胞減少髮生率35.5%.WHO毒副反應標準Ⅲ度非血液學毒性乏力、嘔吐和便祕髮生率分彆為22.0%、14.0%和8.0%,因毒性反應終止治療共5例.結論 長春瑞濱與鉑類聯閤治療高齡非小細胞肺癌有效且毒副反應可耐受.療效穩定的患者也可從化療受益.
목적 연구장춘서빈여박류연합치료70세이상비소세포폐암환자적료효화독부반응.방법 노년폐암환자공입선100례.화료조50례,채용장춘서빈25 mg/m2제1천화제5천,순박60～70mg/m2혹잡박250 mg/m2제2천,매4주위1개주기,련용2～4주기.대조조50례,위동기70세이상환자,자료완정차미주치료.결과 치료조45례가평개료효,부분완해16례,유효솔35.6%,1년생존솔37.8%,중위생존기9.8개월;대조조중위생존기4.0개월.치료조50례균가평개독부반응,세계위생조직(WHO)독부반응표준Ⅲ도백세포、중성백세포、빈혈발생솔분별위38.0%、52.0%화2.2%,IV도중성립세포감소발생솔35.5%.WHO독부반응표준Ⅲ도비혈액학독성핍력、구토화편비발생솔분별위22.0%、14.0%화8.0%,인독성반응종지치료공5례.결론 장춘서빈여박류연합치료고령비소세포폐암유효차독부반응가내수.료효은정적환자야가종화료수익.
Objective To investigated the efficacy and toxic effects of combined chemotherapy of vinorelbine plus cisplatin or carboplatin in patients aged ≥ 70 years and with non-small cell lung cancer (NSCLC).Methods One hundred patients with lung cancer aged ≥70 years were enrolled in the study.Fifty patients in chemotherapy group were assigned to receive vinorelbine 25 mg/m2 at the first day and the fifth day plus cisplatin 60-70 mg/m2 or carboplatin 250 mg/m2 at the second day.All treatments were repeated every 3 or 4 weeks.Another fifty patients aged ≥ 70 years were taken as control group, not receiving treatment.The primary endpoint was survival.Results Forty-five patients were evaluable for response and the partial remission rate was 35.6% (16/45).One year survival rate was 37.8% and median survival time was 9.75 months in chemotherapy group.The median survival time was 4.0 months for patients in control group.All 50 patients in chemotherapy group were evaluable for toxic side effects.WHO grade Ⅲ incidences of leucopoenia, neutropenia and anemia were 38.0%, 52.0% and 2.2%, respectively.Grade IV incidence of neutropenia was 35.5%.WHO grade Ⅲ incidences of fatigue, constipation and vomit were 22.0%, 8.0% and 14.8%,respectively.Five patients failed to complete the treatment due to side effects.Conclusions Combined chemotherapy of vinorelbine plus platinum drugs is effective and tolerated in patients aged over 70 years with advanced NSCLC.Even patients with stable clinical effects shows benefit of survival time.
